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Malignant thymoma is rarely associated with giant cell myocarditis. We present a case study that illustrates this association and
cardiogenic shock with underlying tamponade. The dramatic presentation of this scenario has not been previously described.
1.Introduction
Giant cell myocarditis (GCM) is a rare and frequently fatal
type of myocarditis. Patients usually die of heart failure and
ventricular arrhythmia unless cardiac transplantation is per-
formed [1]. In addition to the idiopathic or primary form,
GCM has been associated with other conditions including
autoimmune diseases, granulomatosis, and neoplastic con-
ditions [2]. However, the etiology and pathogenesis of GCM
is not well known.
Very few cases of malignant thymoma with GCM have
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clinical presentation of cardiac tamponade and cardiogenic
shock.
2.CaseReport
A previously healthy 55-year-old woman presented with
one-week history of worsening muscle weakness, diplopia,
and exertional dyspnea. Physical examination revealed
a pale thin female with tachycardia (107beats/minute),
tachypnea (22breaths/minute), hypotension (blood pressure
86/50mmHg), jugular venous distension with rapid “×”
descent, and distant heart sounds. While the patient was
being evaluated in the emergency room, she suddenly had
a cardiopulmonary arrest. After resuscitation, an echocar-
diogram revealed severe left ventricular (LV) dysfunction
with cardiac tamponade. Emergent pericardiocentesis was
done and 50mL of pericardial ﬂuid was drained. An extra-
pericardial mass compressing the left atrium was also sus-
pected, but images were limited. Electrocardiogram showed
1mmSTsegmentelevationinanteriorchestleads(Figure 1).
Initial labs revealed elevated troponin I (8.38ng/mL) and
creatinekinase-MB(21ng/mL).Sincethissuggestedpossible
acute myocardial infarction, she was emergently taken for
cardiac catheterization, but no coronary artery disease
was detected. She was hemodynamically sustained with
inotropes and an intraaortic balloon pump (IABP).
Transesophageal echocardiogram showed global LV
severe hypokinesis with ejection fraction (EF) of 10 percent
and a large mass indenting the left atrium and pulmonary
veins (Figures 2(a) and 2(b)). On CT scan, a large superior
mediastinal mass extended to the aortopulmonary window
and abutted the aortic arch and pulmonary artery (Figure 3).
CT guided biopsy revealed thymoma with undiﬀerentiated
cells.
Further laboratory evaluation showed elevated acetyl-
choline receptor antibody, antisarcolemma, and antimyosin
antibody titers. Antibody titers of viral etiologies for myoca-
rditis were negative. Steroids and plasmapheresis for thy-
moma-associated myasthenia gravis resulted in neurological
improvement. Patient was taken oﬀ of inotropes and IABP. A
repeat echocardiogram several days later showed improved2 Cardiology Research and Practice
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Figure 1: Electrocardiogram showing ST segment elevation in leads I, aVL, and V2–V6.
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Figure 2: (a) Transesophageal echocardiogram of 4-chamber view showing tumor mass (T) compressing the left atrium (LA). A pericardial
eﬀusion (PE) is adjacent to the left ventricular (LV) free wall. RV = right ventricle. (b) Transesophageal echocardiogram of left ventricular
(LV) outﬂow tract in long axis showing homogenous tumor (T) mass with lucent spaces (∗) compressing the left atrium (LA). AO =
Ascending aorta. RV = right ventricle.
Lossy wavelet compression (4 : 10)
Figure 3: Computed axial tomogram showing a mass in left anterior mediastinum at the root of pulmonary artery with right anterior
pericardial involvement and eﬀusion.
LV function with an EF of 45% (Figure 4). Chemotherapy
with carboplatin and paclitaxel resulted in good initial
response with CT scan showing reduction in thymoma
tumor burden. However, hospital course was complicated by
febrileneutropeniaandsepsis.Shedied35daysafterhospital
admission.
On autopsy, the heart weighed 439grams and was
uniformly soft and pale without coronary obstruction
or valvular abnormality. Histological examination of the
myocardium showed large multinucleated epitheliod cells,
plasma cells, and lymphocytes characteristic of GCM
(Figure 5).
3. Discussion
GCM has a rare association with malignant thymoma with
or without clinical manifestations of myasthenia gravis [2–
4]. Pathogenesis is unknown and prognosis is very poor. In
an animal model, a disorder similar to GCM was induced
by immunization with cardiac myosin [5]. Myasthenia gravis
is an autoimmune disorder and is found to be associated
with thymoma in about 15% of the cases. Association of
giant cell myocarditis with thymoma, myasthenia gravis,
and other autoimmune disorders suggests that it may be
another manifestation of “immune dysregulation”. In thisCardiology Research and Practice 3
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Figure 4: Parasternal long-axis views showing severe baseline LV dysfunction (Figures 4(a) and 4(b)) and improved ejection fraction on the
followup study (Figures 4(c) and 4(d)).
Figure 5: Histopathology demonstrating multinucleated giant cells
and numerous lymphocytes inﬁltrating the cardiomyocytes.
casereport,myastheniagraviswasconﬁrmedbyﬁndinghigh
titers of acetylcholine receptor antibodies. Other nonspeciﬁc
antibodies like antisarcolemma and antimyosin antibodies
provided suggestive evidence that GCM is an autoimmune
disease of the myocardium.
Presentation and clinical course of GCM is usually
characterized by rapid deterioration in LV function, frequent
ventricular arrhythmias, and heart block [1]. In our patient,
cardiac tamponade and cardiogenic shock was secondary to
underlying GCM. Our patient had fulminant presentation;
however, no signiﬁcant ventricular arrhythmia was seen.
Unlike other types of myocarditis, GCM has been shown
to respond to immunosuppressive therapy with signiﬁcant
improvement in survival [1, 6]. Improvement in LV function
in our patient may have been due to immunosuppressive
drug treatment, though she died because of sepsis. Autopsy
conﬁrmed GCM and its rare association with malignant
thymoma.
4. Conclusion
This case illustrates the unusual association of thymoma
and myasthenia gravis with fulminant myocarditis. To our
knowledge, thymoma-associated GCM presenting as cardiac
tamponade and cardiogenic shock has not been reported.
Myocarditis was likely due to autoantibodies. Immunosup-
pressive therapy was associated with improved LV function,
but ultimately fatal sepsis. This case also highlights the
systemic nature of malignant thymoma.
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